Table 6: Summary of recommended frequencies of laboratory monitoring for patients with RA receiving .

LipidsAST and ALTNeutrophils and platelets

MTX, LEF, SSZInitially: every 2–4 weeks
After ~1–3 months: every 1–3 months 
After ~6–2 months: every 3 months or based on clinical judgment
Initially: every 2–4 weeks 
After ~1–3 months: every 1–3 months 
After ~6–12 months: every 3 months or based on clinical judgment

GLUInitially: 1 month after initiation
After 1 month: every 6–12 months

TCZInitially: 4–8 weeks after initiation
After 1–2 months: every 6 months
Initially: 4–8 weeks after initiation 
After 1-2 months: every 3 months
Initially: 4–8 weeks after initiation 
After 1-2 months: every 3 months

TOFInitially: 4–8 weeks after initiationRoutineInitially: 4–8 weeks after initiation 
After 1-2 months: every 3 months

RTXEvery 2-3 months

aTNFaTNFs administered in combination with MTX should follow the MTX monitoring guidelinesaTNFs administered in combination with MTX should follow the MTX monitoring guidelines

ALT, alanine aminotransferase; AST, aspartate aminotransferase; aTNF, anti-tumor necrosis factor agent; DMARD, disease-modifying antirheumatic drug; GLU, glucocorticoid; LEF, leflunomide; MTX, methotrexate; RA, rheumatoid arthritis; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab; TOF, tofacitinib. , golimumab, and rituximab are indicated for RA only when administered in combination with MTX. Monitoring frequency should follow that of the recommendations for MTX.